BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships
出版年份 2012 全文链接
标题
BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships
作者
关键词
-
出版物
BLOOD
Volume 121, Issue 3, Pages 489-498
出版商
American Society of Hematology
发表日期
2012-12-06
DOI
10.1182/blood-2012-05-431379
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- BCR-ABL1 kinase domain mutations: Methodology and clinical evaluation
- (2011) Mary Alikian et al. AMERICAN JOURNAL OF HEMATOLOGY
- BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet
- (2011) S. Soverini et al. BLOOD
- Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profile
- (2011) W. T. Parker et al. BLOOD
- The ABL Switch Control Inhibitor DCC-2036 Is Active against the Chronic Myeloid Leukemia Mutant BCR-ABLT315I and Exhibits a Narrow Resistance Profile
- (2011) C. A. Eide et al. CANCER RESEARCH
- Sensitive Detection ofBCR-ABL1Mutations in Patients With Chronic Myeloid Leukemia After Imatinib Resistance Is Predictive of Outcome During Subsequent Therapy
- (2011) Wendy T. Parker et al. JOURNAL OF CLINICAL ONCOLOGY
- Identifying cancer driver genes in tumor genome sequencing studies
- (2010) Ahrim Youn et al. BIOINFORMATICS
- Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms
- (2010) F. X. Schaub et al. BLOOD
- Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
- (2010) Hagop Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
- (2010) Giuseppe Saglio et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations
- (2009) M. C. Muller et al. BLOOD
- Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors
- (2009) S. Soverini et al. BLOOD
- Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?
- (2009) S. Branford et al. BLOOD
- The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up
- (2009) R. J. Garg et al. BLOOD
- AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
- (2009) Thomas O'Hare et al. CANCER CELL
- The cancer genome
- (2009) Michael R. Stratton et al. NATURE
- Finding of Kinase Domain Mutations in Patients With Chronic Phase Chronic Myeloid Leukemia Responding to Imatinib May Identify Those at High Risk of Disease Progression
- (2008) Jamshid S. Khorashad et al. JOURNAL OF CLINICAL ONCOLOGY
- Imatinib for Newly Diagnosed Patients With Chronic Myeloid Leukemia: Incidence of Sustained Responses in an Intention-to-Treat Analysis
- (2008) Hugues de Lavallade et al. JOURNAL OF CLINICAL ONCOLOGY
- Activity of Bosutinib, Dasatinib, and Nilotinib Against 18 Imatinib-Resistant BCR/ABL Mutants
- (2008) Sara Redaelli et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now